GlassScriptPhysician profile
Netsanet Tefera
NPI 1154973147
$6,081.12
in general payments reported to CMS, 2019-2025
36 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $862 · 2022: $677 · 2023: $1,697 · 2024: $1,615 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,457 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,456.74 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $790.46 | 2021-2025 | Evenity, Prolia, Prolia |
| Abbott Laboratories | $708.87 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $573.43 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $448.71 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $351.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $333.00 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $279.19 | 2021-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $274.56 | 2021 | |
| Sumitomo Pharma America, INC. | $241.58 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $219.14 | 2021-2025 | |
| Abbvie INC. | $211.69 | 2021-2025 | |
| Exact Sciences Corporation | $182.14 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $177.22 | 2023 | Adlarity |
| Dexcom, INC. | $174.04 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $154.97 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.96 | 2024-2025 | Ofev, Jascayd, Jardiance |
| Lilly USA, LLC | $109.95 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $101.23 | 2022-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $86.06 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.61 | 2022-2024 | Cycloset, Xifaxan, Trulance |
| Eisai INC. | $61.85 | 2024-2025 | |
| Dynavax Technologies Corporation | $55.82 | 2023-2025 | Heplisav-B |
| Esperion Therapeutics, INC. | $45.88 | 2021-2022 | |
| Inspire Medical Systems, INC. | $38.77 | 2024 | Inspire |
| Avvisto Therapeutics, LLC | $33.11 | 2024 | Cycloset |
| Merck Sharp & Dohme LLC | $31.50 | 2021 | |
| Bioventus LLC | $29.57 | 2023 | Durolane |
| Phathom Pharmaceuticals, INC. | $27.21 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $25.63 | 2022 | |
| Amarin Pharma, INC. | $19.19 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.40 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.16 | 2023 | Quviviq |
| Viatris Specialty LLC | $17.30 | 2025 | Yupelri |
| Genentech USA, INC. | $16.93 | 2021 | |
| Opko Pharmaceuticals, LLC | $15.52 | 2024 | Rayaldee |
| Horizon Therapeutics Plc | $14.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Netsanet Tefera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.